Rofecoxib en es it fr

Rofecoxib Brand names, Rofecoxib Analogs

Rofecoxib Brand Names Mixture

  • No information avaliable

Rofecoxib Chemical_Formula


Rofecoxib RX_link

Rofecoxib fda sheet

Rofecoxib FDA

Rofecoxib msds (material safety sheet)

Rofecoxib Synthesis Reference

No information avaliable

Rofecoxib Molecular Weight

314.357 g/mol

Rofecoxib Melting Point

No information avaliable

Rofecoxib H2O Solubility


Rofecoxib State


Rofecoxib LogP


Rofecoxib Dosage Forms

Tablet (12.5 mg, 25 mg, or 50 mg); Oral suspension (12.5 or 25 mg per 5 mL solution)

Rofecoxib Indication

For the treatment of osteoarthritis, acute pain in adults and menstrual pain.

Rofecoxib Pharmacology

Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Rofecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain. Unlike celecoxib, rofecoxib lacks a sulfonamide chain and does not require CYP450 enzymes for metabolism.

Rofecoxib Absorption

The mean oral bioavailability of rofecoxib at therapeutically recommended doses of 12.5, 25, and 50 mg is approximately 93%.

Rofecoxib side effects and Toxicity

No overdoses of rofecoxib were reported during clinical trials. Administration of single doses of rofecoxib 1000 mg to 6 healthy volunteers and multiple doses of 250 mg/day for 14 days to 75 healthy volunteers did not result in serious toxicity.

Rofecoxib Patient Information


Physicians should instruct their patients to read the patient package insert before starting therapy with VIOXX and to reread
it each time the prescription is renewed in case any information has changed.

VIOXX can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in
hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms,
patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing
any indicative signs or symptoms. Patients should be apprised of the importance of this follow-up. Risk of GI Ulceration, Bleeding
and Perforation. Patients should be informed that VIOXX is not a substitute for aspirin for cardiovascular prophylaxis because of
its lack of effect on platelets. For additional cardiovascular safety information see CLINICAL STUDIES, Special Studies, VIGOR and
PRECAUTIONS, Cardiovascular Effects.

Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain,
edema or chest pain to their physicians.

Rofecoxib Organisms Affected

Humans and other mammals